Additionally, the 36-month beta value for CLOV is 2.03. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”

The average price predicted by analysts for CLOV is $1.33, which is $0.31 above the current price. The public float for CLOV is 370.52M and currently, short sellers hold a 6.52% ratio of that float. The average trading volume of CLOV on November 20, 2023 was 4.00M shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


CLOV) stock’s latest price update

Clover Health Investments Corp (NASDAQ: CLOV) has seen a decline in its stock price by -1.92 in relation to its previous close of 1.04. However, the company has experienced a 12.94% gain in its stock price over the last five trading sessions. InvestorPlace reported 2023-10-21 that The recent strikes by Kaiser Permanente workers speak to greater structural issues that threaten weaker healthcare stocks in general. It’s clear that healthcare firms are increasingly under greater pressure to improve working conditions.

CLOV’s Market Performance

Clover Health Investments Corp (CLOV) has experienced a 12.94% rise in stock performance for the past week, with a 8.43% rise in the past month, and a -23.31% drop in the past quarter. The volatility ratio for the week is 7.45%, and the volatility levels for the past 30 days are at 7.61% for CLOV. The simple moving average for the last 20 days is 6.25% for CLOV stock, with a simple moving average of -1.33% for the last 200 days.

Analysts’ Opinion of CLOV

Many brokerage firms have already submitted their reports for CLOV stocks, with Cowen repeating the rating for CLOV by listing it as a “Market Perform.” The predicted price for CLOV in the upcoming period, according to Cowen is $3 based on the research report published on February 02, 2022 of the previous year 2022.

CLOV Trading at -1.91% from the 50-Day Moving Average

After a stumble in the market that brought CLOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.42% of loss for the given period.

Volatility was left at 7.61%, however, over the last 30 days, the volatility rate increased by 7.45%, as shares surge +3.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.73% lower at present.

During the last 5 trading sessions, CLOV rose by +12.94%, which changed the moving average for the period of 200-days by -22.14% in comparison to the 20-day moving average, which settled at $0.9616. In addition, Clover Health Investments Corp saw 9.74% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CLOV starting from Loengard Anna U, who purchase 11,000 shares at the price of $1.30 back on Sep 06. After this action, Loengard Anna U now owns 10,000 shares of Clover Health Investments Corp, valued at $14,300 using the latest closing price.

Stock Fundamentals for CLOV

Current profitability levels for the company are sitting at:

The net margin for Clover Health Investments Corp stands at -9.72. The total capital return value is set at -80.57, while invested capital returns managed to touch -74.31. Equity return is now at value -63.58, with -17.34 for asset returns.

Based on Clover Health Investments Corp (CLOV), the company’s capital structure generated 1.69 points at debt to equity in total, while total debt to capital is 1.66. Total debt to assets is 0.72, with long-term debt to equity ratio resting at 1.16. Finally, the long-term debt to capital ratio is 1.14.

When we switch over and look at the enterprise to sales, we see a ratio of 0.16, with the company’s debt to enterprise value settled at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.42.


In conclusion, Clover Health Investments Corp (CLOV) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.